Bethany J Foster1, Ahna L H Pai2, Nataliya Zelikovsky3, Sandra Amaral4, Lorraine Bell5, Vikas R Dharnidharka6, Diane Hebert7, Crystal Holly8, Baerbel Knauper9, Douglas Matsell10, Veronique Phan11, Rachel Rogers3, Jodi M Smith12, Huaqing Zhao13, Susan L Furth4. 1. Montreal Children's Hospital, McGill University, Montreal, QC, Canada; Department of Pediatrics, McGill University, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada. Electronic address: bethany.foster@mcgill.ca. 2. Center for Adherence and Self-Management, Cincinnati Children's Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine Cincinnati OH. 3. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA. 4. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA. 5. Montreal Children's Hospital, McGill University, Montreal, QC, Canada; Department of Pediatrics, McGill University, Montreal, QC, Canada. 6. Department of Pediatrics, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO. 7. Department of Pediatrics, Hospital for Sick Children, Toronto, ON. 8. Department of Psychology, University of Ottawa, Ottawa, ON. 9. Department of Psychology, McGill University, Montreal, QC. 10. British Columbia Children's Hospital, University of British Columbia, Vancouver, BC. 11. Centre Hospitalier Universitaire Ste-Justine, Montreal, QC, Canada. 12. Seattle Children's Hospital, Seattle, WA. 13. Department of Clinical Sciences, Temple University School of Medicine, Philadelphia, PA.
Abstract
BACKGROUND: Poor adherence to immunosuppressive medications is a major cause of premature graft loss among children and young adults. Multicomponent interventions have shown promise but have not been fully evaluated. STUDY DESIGN: Unblinded parallel-arm randomized trial to assess the efficacy of a clinic-based adherence-promoting intervention. SETTING & PARTICIPANTS: Prevalent kidney transplant recipients 11 to 24 years of age and 3 or more months posttransplantation at 8 kidney transplantation centers in Canada and the United States (February 2012 to May 2016) were included. INTERVENTION: Adherence was electronically monitored in all participants during a 3-month run-in, followed by a 12-month intervention. Participants assigned to the TAKE-IT intervention could choose to receive text message, e-mail, and/or visual cue dose reminders and met with a coach at 3-month intervals when adherence data from the prior 3 months were reviewed with the participant. "Action-Focused Problem Solving" was used to address adherence barriers selected as important by the participant. Participants assigned to the control group met with coaches at 3-month intervals but received no feedback about adherence data. OUTCOMES: The primary outcomes were electronically measured "taking" adherence (the proportion of prescribed doses of immunosuppressive medications taken) and "timing" adherence (the proportion of doses of immunosuppressive medications taken between 1 hour before and 2 hours after the prescribed time of administration) on each day of observation. Secondary outcomes included the standard deviation of tacrolimus trough concentrations, self-reported adherence, acute rejection, and graft failure. RESULTS:81 patients were assigned to intervention (median age, 15.5 years; 57% male) and 88 to the control group (median age, 15.8 years; 61% male). Electronic adherence data were available for 64 intervention and 74 control participants. Participants in the intervention group had significantly greater odds of taking prescribed medications (OR, 1.66; 95% CI, 1.15-2.39) and taking medications at or near the prescribed time (OR, 1.74; 95% CI, 1.21-2.50) than controls. LIMITATIONS: Lack of electronic adherence data for some participants may have introduced bias. There was low statistical power for clinical outcomes. CONCLUSIONS: The multicomponent TAKE-IT intervention resulted in significantly better medication adherence than the control condition. Better medication adherence may result in improved graft outcomes, but this will need to be demonstrated in larger studies. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01356277.
RCT Entities:
BACKGROUND: Poor adherence to immunosuppressive medications is a major cause of premature graft loss among children and young adults. Multicomponent interventions have shown promise but have not been fully evaluated. STUDY DESIGN: Unblinded parallel-arm randomized trial to assess the efficacy of a clinic-based adherence-promoting intervention. SETTING & PARTICIPANTS: Prevalent kidney transplant recipients 11 to 24 years of age and 3 or more months posttransplantation at 8 kidney transplantation centers in Canada and the United States (February 2012 to May 2016) were included. INTERVENTION: Adherence was electronically monitored in all participants during a 3-month run-in, followed by a 12-month intervention. Participants assigned to the TAKE-IT intervention could choose to receive text message, e-mail, and/or visual cue dose reminders and met with a coach at 3-month intervals when adherence data from the prior 3 months were reviewed with the participant. "Action-Focused Problem Solving" was used to address adherence barriers selected as important by the participant. Participants assigned to the control group met with coaches at 3-month intervals but received no feedback about adherence data. OUTCOMES: The primary outcomes were electronically measured "taking" adherence (the proportion of prescribed doses of immunosuppressive medications taken) and "timing" adherence (the proportion of doses of immunosuppressive medications taken between 1 hour before and 2 hours after the prescribed time of administration) on each day of observation. Secondary outcomes included the standard deviation of tacrolimus trough concentrations, self-reported adherence, acute rejection, and graft failure. RESULTS: 81 patients were assigned to intervention (median age, 15.5 years; 57% male) and 88 to the control group (median age, 15.8 years; 61% male). Electronic adherence data were available for 64 intervention and 74 control participants. Participants in the intervention group had significantly greater odds of taking prescribed medications (OR, 1.66; 95% CI, 1.15-2.39) and taking medications at or near the prescribed time (OR, 1.74; 95% CI, 1.21-2.50) than controls. LIMITATIONS: Lack of electronic adherence data for some participants may have introduced bias. There was low statistical power for clinical outcomes. CONCLUSIONS: The multicomponent TAKE-IT intervention resulted in significantly better medication adherence than the control condition. Better medication adherence may result in improved graft outcomes, but this will need to be demonstrated in larger studies. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01356277.
Authors: Sebastian Bonner; Barry J Zimmerman; David Evans; Matilde Irigoyen; David Resnick; Robert B Mellins Journal: J Asthma Date: 2002-04 Impact factor: 2.515
Authors: Robert Gross; Scarlett L Bellamy; Jennifer Chapman; Xiaoyan Han; Jacqueline O'Duor; Steven C Palmer; Peter S Houts; James C Coyne; Brian L Strom Journal: JAMA Intern Med Date: 2013-02-25 Impact factor: 21.873
Authors: Tonja R Nansel; Ronald J Iannotti; Bruce G Simons-Morton; Leslie P Plotnick; Loretta M Clark; Linda Zeitzoff Journal: Diabetes Care Date: 2009-02-10 Impact factor: 19.112
Authors: J J Kim; R Balasubramanian; G Michaelides; P Wittenhagen; N J Sebire; N Mamode; O Shaw; R Vaughan; S D Marks Journal: Am J Transplant Date: 2014-08-28 Impact factor: 8.086
Authors: Jessica K Stevenson; Zoe C Campbell; Angela C Webster; Clara K Chow; Allison Tong; Jonathan C Craig; Katrina L Campbell; Vincent Ws Lee Journal: Cochrane Database Syst Rev Date: 2019-08-06
Authors: Cynthia L Russell; Donna Hathaway; Laura M Remy; Dana Aholt; Debra Clark; Courtney Miller; Catherine Ashbaugh; Mark Wakefield; Sangbeak Ye; Vincent S Staggs; Rebecca J Ellis; Kathy Goggin Journal: Am J Transplant Date: 2019-08-20 Impact factor: 8.086
Authors: Julie Boucquemont; Ahna L H Pai; Vikas R Dharnidharka; Diane Hebert; Susan L Furth; Bethany J Foster Journal: Transplantation Date: 2019-04 Impact factor: 4.939
Authors: Haley M Gonzales; James N Fleming; Mulugeta Gebregziabher; Maria Aurora Posadas-Salas; Zemin Su; John W McGillicuddy; David J Taber Journal: Clin J Am Soc Nephrol Date: 2021-04-30 Impact factor: 8.237